GT Biopharma increases Series M preferred stock private placement to $7.75 million
On September 18, 2026, GT Biopharma amended its September 14 securities purchase agreement to add a new purchaser and raise the preferred stock offering to 8,611.111 shares with an aggregate purchase price of $7,750,000. The amendment also gives purchasers rights to buy additional preferred stock for an aggregate purchase price of $31,208,054, and the company increased its designated Series M preferred shares from 41,778 to 43,287, with the shares and warrants sold under Rule 506(b) and a resale registration statement to be filed.
Key points
- Preferred stock offering increased to 8,611.111 shares of Series M 10% Convertible Preferred Stock, with an aggregate stated value of $8,611,111.11 and an aggregate purchase price of $7,750,000.
- Purchasers may elect additional preferred stock purchases (Greenshoe Rights) with an aggregate stated value of up to $34,675,615 for an aggregate purchase price of $31,208,054.
- Certificate of Increase filed September 18, 2026 raises designated Series M preferred shares from 41,778 to 43,287.
- Company agreed to file a resale registration statement within 30 days after the initial closing and after each Greenshoe closing.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.